MIRM — Mirum Pharmaceuticals Cashflow Statement
0.000.00%
- $2.02bn
- $2.05bn
- $336.89m
- 84
- 16
- 84
- 65
Annual cashflow statement for Mirum Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -103 | -84 | -136 | -163 | -87.9 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 13.3 | -66.3 | 39.9 | 104 | 52 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.611 | 17 | -21.1 | -22.6 | 22.6 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -89.1 | -133 | -120 | -70.9 | 10.3 |
Capital Expenditures | -0.225 | -19 | -0.278 | -20.1 | -21 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 38.1 | 67.6 | 7.98 | -87.1 | -69.1 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 37.9 | 48.5 | 7.7 | -107 | -90.1 |
Financing Cash Flow Items | 49.4 | 64.5 | -5.55 | -196 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 181 | 73.5 | 109 | 337 | 17.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 130 | -10.7 | -3.34 | 158 | -63.4 |